Video

Return of Interferon in RCC

For High-Definition, Click

Although not commonly used, interferon could soon be undergoing a renaissance for patients with renal cell carcinoma (RCC), believes Nicholas J. Vogelzang, MD. This treatment is still commonly used in Japan and will soon be combined with PD-1 inhibitors in clinical trials. It seems likely that interferon will once again have a role for patients with RCC, Vogelzang suggests.

Related Videos
Sam Brondfield, MD, MA
Mary Philip, MD, PhD
Rom S. Leidner, MD
Sarwish Rafiq, PhD
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Salman R. Punekar, MD
Thomas Marron, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
D. Ross Camidge, MD, PhD
Related Content
Justin M. Watts, MD
July 22nd 2024

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
May 2nd 2022

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

Toni Choueiri, MD
July 18th 2024

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition

Sorting Through Sexism, Guilt, and Motherhood in Medicine
January 27th 2022

Sorting Through Sexism, Guilt, and Motherhood in Medicine

Andrea B. Apolo, MD, of the National Institutes of Health
July 15th 2024

Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
July 14th 2024

FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors